Corcept Therapeutics (CORT)
Corcept Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
8.6M
Short interest
settlement 2026-10-15
12.3
Days to cover
+8.7 days vs prior
49.7%
Short share of volume
2026-10-28
70
Fails to deliver
settlement 2026-09-17
Tue 3 Nov
Next earnings
estimated date
-$44.8M
Insider flow, 90 days
0 buys, 46 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CORT is 8,588,418 shares, down 762,496 shares over the last month. Over the last 48 readings it ranged from 8,186,385 shares (15 January 2026) to 18,798,697 shares (31 October 2024). The latest reading sits at the bottom of that range. At the reported average volume of 699K shares a day that is 12.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/cort" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 8,588,418 | +0.6% | 698,644 | 12.29 |
| 2026-09-30 | 8,540,393 | -8.7% | 2,389,305 | 3.57 |
| 2026-09-15 | 9,350,914 | -0.5% | 944,042 | 9.91 |
| 2026-08-31 | 9,399,154 | -3.1% | 789,538 | 11.90 |
| 2026-08-14 | 9,696,757 | -1.3% | 927,931 | 10.45 |
| 2026-07-31 | 9,819,732 | +4.0% | 1,538,603 | 6.38 |
| 2026-07-15 | 9,442,750 | +9.3% | 1,086,067 | 8.69 |
| 2026-06-30 | 8,641,452 | +0.8% | 1,027,184 | 8.41 |
| 2026-06-15 | 8,569,293 | -2.5% | 969,260 | 8.84 |
| 2026-05-29 | 8,793,063 | -5.6% | 1,028,716 | 8.55 |
| 2026-05-15 | 9,315,811 | -13.0% | 1,479,014 | 6.30 |
| 2026-04-30 | 10,710,814 | -5.6% | 932,253 | 11.49 |
| 2026-04-15 | 11,342,506 | -8.9% | 1,168,808 | 9.70 |
| 2026-03-31 | 12,449,551 | -4.4% | 2,503,526 | 4.97 |
| 2026-03-13 | 13,027,166 | +4.5% | 1,167,586 | 11.16 |
| 2026-02-27 | 12,465,750 | +24.1% | 2,607,275 | 4.78 |
| 2026-02-13 | 10,042,591 | +8.3% | 1,193,150 | 8.42 |
| 2026-01-30 | 9,277,014 | +13.3% | 2,674,324 | 3.47 |
| 2026-01-15 | 8,186,385 | -10.5% | 2,578,035 | 3.18 |
| 2025-12-31 | 9,148,004 | -9.5% | 3,008,944 | 3.04 |
| 2025-12-15 | 10,108,719 | -2.3% | 875,407 | 11.55 |
| 2025-11-28 | 10,341,891 | +1.7% | 522,876 | 19.78 |
| 2025-11-14 | 10,166,733 | -8.0% | 730,258 | 13.92 |
| 2025-10-31 | 11,046,701 | +7.9% | 778,500 | 14.19 |
| 2025-10-15 | 10,239,885 | -3.8% | 1,048,259 | 9.77 |
| 2025-09-30 | 10,644,876 | -1.5% | 1,067,761 | 9.97 |
| 2025-09-15 | 10,805,275 | -0.7% | 685,211 | 15.77 |
| 2025-08-29 | 10,881,585 | +2.8% | 622,278 | 17.49 |
| 2025-08-15 | 10,590,834 | -4.1% | 891,285 | 11.88 |
| 2025-07-31 | 11,045,208 | -1.6% | 767,060 | 14.40 |
| 2025-07-15 | 11,223,626 | -1.9% | 1,049,140 | 10.70 |
| 2025-06-30 | 11,446,765 | -9.5% | 2,044,047 | 5.60 |
| 2025-06-13 | 12,652,014 | +0.1% | 1,718,555 | 7.36 |
| 2025-05-30 | 12,635,387 | +1.2% | 1,063,058 | 11.89 |
| 2025-05-15 | 12,481,476 | -5.3% | 1,308,595 | 9.54 |
| 2025-04-30 | 13,183,760 | +7.3% | 1,385,429 | 9.52 |
| 2025-04-15 | 12,287,228 | -25.6% | 2,405,903 | 5.11 |
| 2025-03-31 | 16,526,709 | +1.2% | 2,064,502 | 8.01 |
| 2025-03-14 | 16,329,860 | +1.8% | 1,295,113 | 12.61 |
| 2025-02-28 | 16,042,575 | +4.2% | 1,306,590 | 12.28 |
| 2025-02-14 | 15,392,421 | -2.6% | 779,480 | 19.75 |
| 2025-01-31 | 15,811,989 | -2.7% | 994,237 | 15.90 |
| 2025-01-15 | 16,258,254 | +1.9% | 734,458 | 22.14 |
| 2024-12-31 | 15,958,163 | +1.5% | 825,016 | 19.34 |
| 2024-12-13 | 15,715,773 | -7.8% | 837,977 | 18.75 |
| 2024-11-29 | 17,051,615 | -7.0% | 731,719 | 23.30 |
| 2024-11-15 | 18,344,291 | -2.4% | 1,170,027 | 15.68 |
| 2024-10-31 | 18,798,697 | -9.1% | 1,265,260 | 14.86 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of CORT volume is 49.7%, up 4.8 points over the last five sessions. Over the last 30 readings it ranged from 26.2% (28 September 2026) to 72.2% (17 September 2026). The latest reading is in line with the 30-session average of 50.9%, on 431K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 215K | 431K | 49.7% | 500 |
| 2026-10-27 | 153K | 367K | 41.6% | 0 |
| 2026-10-26 | 442K | 763K | 57.9% | 15,684 |
| 2026-10-23 | 707K | 1.2M | 58.6% | 30,449 |
| 2026-10-22 | 157K | 326K | 48.0% | 250 |
| 2026-10-21 | 82K | 182K | 44.9% | 28 |
| 2026-10-20 | 71K | 136K | 52.0% | 182 |
| 2026-10-19 | 54K | 118K | 46.2% | 117 |
| 2026-10-16 | 106K | 254K | 41.6% | 336 |
| 2026-10-15 | 138K | 251K | 55.0% | 236 |
| 2026-10-14 | 160K | 266K | 60.1% | 0 |
| 2026-10-13 | 109K | 238K | 45.8% | 600 |
| 2026-10-12 | 84K | 201K | 41.8% | 5 |
| 2026-10-09 | 115K | 201K | 57.1% | 3,002 |
| 2026-10-08 | 111K | 195K | 57.1% | 32 |
| 2026-10-07 | 134K | 221K | 60.9% | 18 |
| 2026-10-06 | 147K | 281K | 52.2% | 0 |
| 2026-10-05 | 156K | 299K | 52.1% | 0 |
| 2026-10-02 | 211K | 314K | 67.0% | 2,533 |
| 2026-10-01 | 165K | 336K | 49.2% | 170 |
| 2026-09-30 | 144K | 274K | 52.4% | 57 |
| 2026-09-29 | 157K | 350K | 45.0% | 0 |
| 2026-09-28 | 114K | 437K | 26.2% | 0 |
| 2026-09-25 | 137K | 265K | 51.7% | 0 |
| 2026-09-24 | 136K | 275K | 49.6% | 0 |
| 2026-09-23 | 138K | 291K | 47.4% | 154 |
| 2026-09-22 | 114K | 249K | 45.7% | 0 |
| 2026-09-21 | 136K | 459K | 29.7% | 0 |
| 2026-09-18 | 577K | 833K | 69.3% | 5,407 |
| 2026-09-17 | 270K | 374K | 72.2% | 463 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 17 September 2026, the fails-to-deliver balance in CORT is 70 shares, down 31,007 shares over the last settlement date. Over the last 30 readings it ranged from 12 shares (27 July 2026) to 242,856 shares (31 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-17 | 70 | $111.81 | $8K |
| 2026-09-03 | 31,077 | $110.43 | $3.4M |
| 2026-08-28 | 399 | $116.93 | $47K |
| 2026-08-21 | 1,245 | $121.05 | $151K |
| 2026-08-17 | 9,969 | $114.47 | $1.1M |
| 2026-07-31 | 242,856 | $118.32 | $28.7M |
| 2026-07-28 | 2,575 | $91.12 | $235K |
| 2026-07-27 | 12 | $95.36 | $1K |
| 2026-07-07 | 24,396 | $91.61 | $2.2M |
| 2026-07-06 | 9,558 | $90.21 | $862K |
| 2026-07-02 | 9,892 | $88.48 | $875K |
| 2026-06-30 | 170 | $87.89 | $15K |
| 2026-06-25 | 752 | $81.56 | $61K |
| 2026-06-23 | 318 | $79.71 | $25K |
| 2026-06-17 | 22,695 | $83.71 | $1.9M |
| 2026-06-16 | 24,342 | $83.12 | $2.0M |
| 2026-06-10 | 173 | $77.49 | $13K |
| 2026-06-01 | 28 | $69.49 | $2K |
| 2026-05-28 | 15,790 | $66.65 | $1.1M |
| 2026-05-18 | 1,066 | $56.37 | $60K |
| 2026-05-05 | 264 | $51.60 | $14K |
| 2026-05-01 | 99,904 | $46.52 | $4.6M |
| 2026-04-30 | 64 | $46.59 | $3K |
| 2026-04-23 | 93 | $46.57 | $4K |
| 2026-04-08 | 19 | $41.69 | $792 |
| 2026-04-06 | 53,237 | $42.49 | $2.3M |
| 2026-03-16 | 104 | $32.15 | $3K |
| 2026-03-13 | 102 | $32.39 | $3K |
| 2026-03-12 | 684 | $33.74 | $23K |
| 2026-03-10 | 697 | $33.99 | $24K |
Insider trades
SEC Form 4, newest first. JSONInsiders at CORT reported 46 open-market sells worth $44.8M in the last 90 days and no open-market buys. Latest filing: WILSON JAMES N (Director) on 2026-10-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | WILSON JAMES N | Director | Sell | 300 | $116.30 | $35K | 1.1M |
| 2026-10-15 | WILSON JAMES N | Director | Sell | 3K | $115.39 | $351K | 1.1M |
| 2026-10-15 | WILSON JAMES N | Director | Sell | 7K | $114.48 | $762K | 1.1M |
| 2026-10-02 | Maduck Sean | See Remarks | Sell | 9K | $116.55 | $1.0M | 10K |
| 2026-10-02 | Maduck Sean | See Remarks | Sell | 16K | $116.12 | $1.8M | 19K |
| 2026-10-02 | Maduck Sean | See Remarks | Exercise or conversion | 25K | $8.27 | $203K | 35K |
| 2026-10-02 | Lyon Joseph Douglas | See Remarks | Sell | 5K | $116.54 | $553K | 6K |
| 2026-10-02 | Lyon Joseph Douglas | See Remarks | Sell | 4K | $115.70 | $514K | 10K |
| 2026-10-02 | Lyon Joseph Douglas | See Remarks | Exercise or conversion | 6K | $19.26 | $112K | 15K |
| 2026-10-02 | Lyon Joseph Douglas | See Remarks | Exercise or conversion | 3K | $13.56 | $46K | 9K |
| 2026-10-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 5K | $116.58 | $600K | 4K |
| 2026-10-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 2K | $115.73 | $241K | 9K |
| 2026-10-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1K | $114.52 | $126K | 11K |
| 2026-10-02 | Vieira Roberto Wandenkolk | President, Oncology | Exercise or conversion | 8K | $21.63 | $180K | 12K |
| 2026-10-01 | Maduck Sean | See Remarks | Sell | 413 | $115.54 | $48K | 10K |
| 2026-10-01 | Maduck Sean | See Remarks | Exercise or conversion | 413 | $8.27 | $3K | 10K |
| 2026-10-01 | Lyon Joseph Douglas | See Remarks | Sell | 810 | $115.40 | $93K | 6K |
| 2026-10-01 | Lyon Joseph Douglas | See Remarks | Exercise or conversion | 810 | $13.56 | $11K | 6K |
| 2026-09-24 | Robb Gary Charles | Chief Business Officer | Gift | 5K | $0.00 | $0 | 21K |
| 2026-09-24 | Robb Gary Charles | Chief Business Officer | Gift | 5K | $0.00 | $0 | 21K |
| 2026-09-24 | Robb Gary Charles | Chief Business Officer | Gift | 17K | $0.00 | $0 | 14K |
| 2026-09-17 | Robb Gary Charles | Chief Business Officer | Exercise or conversion | 17K | $8.27 | $145K | 31K |
| 2026-09-16 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 296 | $100.82 | $30K | 4K |
| 2026-09-15 | WILSON JAMES N | Director | Sell | 3K | $111.70 | $313K | 1.1M |
| 2026-09-15 | WILSON JAMES N | Director | Sell | 400 | $110.84 | $44K | 1.1M |
| 2026-09-15 | WILSON JAMES N | Director | Sell | 7K | $110.27 | $750K | 1.1M |
| 2026-09-14 | Lyon Joseph Douglas | See Remarks | Sell | 2K | $114.12 | $250K | 6K |
| 2026-09-14 | Lyon Joseph Douglas | See Remarks | Sell | 8K | $113.32 | $885K | 8K |
| 2026-09-14 | Lyon Joseph Douglas | See Remarks | Exercise or conversion | 7K | $13.56 | $100K | 16K |
| 2026-09-14 | Lyon Joseph Douglas | See Remarks | Exercise or conversion | 3K | $11.35 | $29K | 8K |
| 2026-09-02 | Maduck Sean | See Remarks | Tax withholding | 117 | $113.38 | $13K | 10K |
| 2026-09-02 | Mokari Atabak | Chief Financial Officer | Tax withholding | 102 | $113.38 | $12K | 16K |
| 2026-09-02 | Robb Gary Charles | Chief Business Officer | Tax withholding | 91 | $113.38 | $10K | 14K |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1K | $115.44 | $141K | 4K |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 6K | $114.58 | $644K | 5K |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 2K | $113.72 | $183K | 11K |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 974 | $112.40 | $109K | 13K |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 2K | $111.37 | $171K | 14K |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 24K | $110.70 | $2.6M | 15K |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 24K | $109.35 | $2.6M | 39K |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Exercise or conversion | 58K | $21.63 | $1.3M | 63K |
| 2026-09-02 | Vieira Roberto Wandenkolk | President, Oncology | Tax withholding | 102 | $113.38 | $12K | 4K |
| 2026-09-02 | Lyon Joseph Douglas | See Remarks | Tax withholding | 72 | $113.38 | $8K | 6K |
| 2026-09-01 | Guyer William | Chief Development Officer | Grant | 164 | $0.00 | $0 | 4K |
| 2026-09-01 | Maduck Sean | See Remarks | Grant | 150 | $0.00 | $0 | 10K |
| 2026-09-01 | Mokari Atabak | Chief Financial Officer | Grant | 138 | $0.00 | $0 | 16K |
| 2026-09-01 | Robb Gary Charles | Chief Business Officer | Grant | 164 | $0.00 | $0 | 14K |
| 2026-09-01 | Vieira Roberto Wandenkolk | President, Oncology | Grant | 138 | $0.00 | $0 | 4K |
| 2026-09-01 | Lyon Joseph Douglas | See Remarks | Grant | 130 | $0.00 | $0 | 6K |
| 2026-09-01 | Guyer William | Chief Development Officer | Grant | 164 | $113.38 | $19K | 4K |
| 2026-09-01 | Maduck Sean | See Remarks | Grant | 150 | $113.38 | $17K | 10K |
| 2026-09-01 | Maduck Sean | See Remarks | Sell | 2K | $115.61 | $264K | 10K |
| 2026-09-01 | Maduck Sean | See Remarks | Sell | 11K | $114.71 | $1.3M | 12K |
| 2026-09-01 | Maduck Sean | See Remarks | Sell | 12K | $113.94 | $1.3M | 23K |
| 2026-09-01 | Maduck Sean | See Remarks | Exercise or conversion | 25K | $8.27 | $207K | 35K |
| 2026-09-01 | Mokari Atabak | Chief Financial Officer | Grant | 138 | $113.38 | $16K | 16K |
| 2026-09-01 | Robb Gary Charles | Chief Business Officer | Grant | 164 | $113.38 | $19K | 14K |
| 2026-09-01 | Vieira Roberto Wandenkolk | President, Oncology | Grant | 138 | $113.38 | $16K | 4K |
| 2026-09-01 | Lyon Joseph Douglas | See Remarks | Grant | 130 | $113.38 | $15K | 6K |
| 2026-08-26 | Park Kimberly | Director | Sell | 27K | $122.55 | $3.3M | 0 |
| 2026-08-26 | Park Kimberly | Director | Tax withholding | 3K | $122.09 | $405K | 27K |
| 2026-08-26 | Park Kimberly | Director | Exercise or conversion | 30K | $13.49 | $405K | 30K |
| 2026-08-25 | Maduck Sean | See Remarks | Sell | 6K | $126.06 | $740K | 10K |
| 2026-08-25 | Maduck Sean | See Remarks | Sell | 25K | $125.47 | $3.1M | 16K |
| 2026-08-25 | Maduck Sean | See Remarks | Exercise or conversion | 31K | $11.35 | $351K | 41K |
| 2026-08-18 | MAHONEY DAVID L | Director | Sell | 400 | $119.64 | $48K | 1.1M |
| 2026-08-18 | MAHONEY DAVID L | Director | Sell | 7K | $118.88 | $839K | 1.1M |
| 2026-08-18 | MAHONEY DAVID L | Director | Sell | 91K | $118.24 | $10.8M | 1.1M |
| 2026-08-18 | MAHONEY DAVID L | Director | Sell | 5K | $117.47 | $585K | 1.2M |
| 2026-08-17 | Robb Gary Charles | Chief Business Officer | Sell | 10K | $116.26 | $1.2M | 40K |
| 2026-08-17 | Robb Gary Charles | Chief Business Officer | Gift | 125 | $0.00 | $0 | 13K |
| 2026-08-14 | Maduck Sean | See Remarks | Sell | 4K | $114.49 | $419K | 10K |
| 2026-08-14 | Maduck Sean | See Remarks | Exercise or conversion | 4K | $8.27 | $30K | 13K |
| 2026-08-14 | WILSON JAMES N | Director | Sell | 2K | $112.64 | $257K | 1.1M |
| 2026-08-14 | WILSON JAMES N | Director | Sell | 5K | $111.44 | $520K | 1.1M |
| 2026-08-14 | WILSON JAMES N | Director | Sell | 3K | $110.49 | $337K | 1.1M |
| 2026-08-12 | Robb Gary Charles | Chief Business Officer | Gift | 3K | $0.00 | $0 | 16K |
| 2026-08-12 | Robb Gary Charles | Chief Business Officer | Gift | 3K | $0.00 | $0 | 16K |
| 2026-08-12 | Robb Gary Charles | Chief Business Officer | Gift | 12K | $0.00 | $0 | 14K |
| 2026-08-10 | Maduck Sean | See Remarks | Sell | 1K | $114.52 | $118K | 10K |
| 2026-08-10 | Maduck Sean | See Remarks | Exercise or conversion | 1K | $8.27 | $9K | 11K |
| 2026-08-10 | Guyer William | Chief Development Officer | Sell | 5K | $114.04 | $544K | 4K |
| 2026-08-10 | Guyer William | Chief Development Officer | Sell | 12K | $113.18 | $1.3M | 9K |
| 2026-08-10 | Guyer William | Chief Development Officer | Exercise or conversion | 16K | $21.65 | $353K | 20K |
| 2026-08-04 | Guyer William | Chief Development Officer | Sell | 4K | $113.12 | $419K | 4K |
| 2026-08-04 | Guyer William | Chief Development Officer | Exercise or conversion | 4K | $21.65 | $80K | 8K |
| 2026-08-03 | Maduck Sean | See Remarks | Sell | 20K | $114.70 | $2.3M | 10K |
| 2026-08-03 | Maduck Sean | See Remarks | Exercise or conversion | 20K | $8.27 | $168K | 30K |
| 2026-08-03 | Lyon Joseph Douglas | See Remarks | Sell | 2K | $114.16 | $176K | 5K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 1K | $120.67 | $121K | 16K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 8K | $119.95 | $972K | 17K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 5K | $118.73 | $568K | 25K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 8K | $117.93 | $975K | 30K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 7K | $116.96 | $829K | 38K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 14K | $115.87 | $1.6M | 45K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 15K | $114.96 | $1.8M | 60K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 5K | $113.18 | $532K | 75K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 600 | $110.95 | $67K | 80K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 2K | $110.03 | $242K | 80K |
| 2026-07-30 | Mokari Atabak | Chief Financial Officer | Sell | 400 | $108.46 | $43K | 83K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON40 Form 144 notices on file for CORT worth $117.2M at the prices reported; 10 in the last 90 days worth $55.0M. Latest: Lyon Joseph Douglas filed on 2026-10-01 to sell 10,000 shares ($1.2M) from 2026-10-01.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-01 | Lyon Joseph DouglasOfficer | 10K | $1.2M | 0.009% | 2026-10-01 | Stifel Nicolaus |
| 2026-09-15 | WILSON JAMES NDirector | 30K | $3.3M | 0.028% | 2026-09-15 | THE CHARLES SCHWAB CORPORATION |
| 2026-09-14 | Lyon Joseph DouglasOfficer | 10K | $1.1M | 0.009% | 2026-09-14 | Stifel Nicholas |
| 2026-09-02 | Vieira Roberto WandenkolkOfficer | 75K | $8.3M | 0.070% | 2026-09-02 | Stifel Nicolaus & Company Inc |
| 2026-08-26 | KIMBERLY PARKDirector | 27K | $3.3M | 0.025% | 2026-08-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-25 | Maduck SeanOfficer | 175K | $22.0M | 0.162% | 2026-08-25 | Stifel Nicolaus & Company Inc |
| 2026-08-18 | MAHONEY DAVID LDirector | 104K | $12.2M | 0.096% | 2026-08-18 | THE CHARLES SCHWAB CORPORATION |
| 2026-08-17 | Robb Gary CharlesOfficer | 10K | $1.2M | 0.009% | 2026-08-17 | Stifel Nicolaus & Company Inc |
| 2026-08-04 | Guyer WilliamOfficer | 20K | $2.3M | 0.019% | 2026-08-04 | Stifel Nicolaus & Company Inc |
| 2026-08-03 | Lyon Joseph DouglasOfficer | 2K | $176K | 0.001% | 2026-08-03 | Stifel Nicolaus & Company Inc |
| 2026-07-30 | Mokari AtabakOfficer | 40K | $4.6M | 0.037% | 2026-07-30 | Stifel Nicolaus & Company Inc |
| 2026-07-07 | Guyer WilliamOfficer | 20K | $1.9M | 0.019% | 2026-07-07 | Stifel Nicolaus & Company Inc |
| 2026-06-16 | MAHONEY DAVID LDirector | 20K | $1.7M | 0.019% | 2026-06-16 | The Charles Schwab Corporation |
| 2026-06-16 | WILSON JAMES NDirector | 30K | $2.5M | 0.028% | 2026-06-16 | THE CHARLES SCHWAB CORPORATION |
| 2026-06-02 | Guyer WilliamOfficer | 20K | $1.4M | 0.019% | 2026-06-02 | Stifel Nicolaus & Company Inc. |
| 2026-06-01 | Mokari AtabakOfficer | 160K | $11.2M | 0.149% | 2026-06-01 | Stifel Nicolaus & Company Inc |
| 2026-06-01 | BELANOFF JOSEPH KOfficer | 13K | $892K | 0.012% | 2026-06-01 | Stifel Nicolaus & Company Inc. |
| 2026-05-27 | Maduck SeanOfficer | 150K | $9.8M | 0.140% | 2026-05-27 | Stifel Nicolaus & Company Inc |
| 2026-05-20 | Lyon Joseph DouglasOfficer | 5K | $291K | 0.005% | 2026-05-20 | Fidelity Brokerage Services LLC |
| 2026-05-05 | Guyer WilliamOfficer | 20K | $1.0M | 0.019% | 2026-05-05 | Stifel Nicolaus & Company Inc. |
| 2026-05-01 | BELANOFF JOSEPH KOfficer | 40K | $1.9M | 0.037% | 2026-05-01 | Stifel Nicolaus & Company Inc. |
| 2026-04-07 | Guyer WilliamOfficer | 20K | $817K | 0.019% | 2026-04-07 | Stifel Nicolaus & Company Inc. |
| 2026-03-25 | BELANOFF JOSEPH KOfficer | 40K | $1.4M | 0.038% | 2026-03-25 | Stifel Nicolaus & Company Inc. |
| 2026-03-04 | Guyer WilliamOfficer | 20K | $706K | 0.019% | 2026-03-04 | Stifel Nicolaus & Company Inc. |
| 2026-02-03 | Guyer WilliamOfficer | 20K | $814K | 0.019% | 2026-02-03 | Stifel Nicolaus & Company Inc. |
| 2026-01-06 | Guyer WilliamOfficer | 20K | $699K | 0.019% | 2026-01-06 | Stifel Nicolaus & Company Inc. |
| 2025-12-02 | Guyer WilliamOfficer | 20K | $1.6M | 0.019% | 2025-12-02 | Stifel Nicolaus & Company Inc. |
| 2025-12-01 | Maduck SeanOfficer | 20K | $1.6M | 0.019% | 2025-12-01 | Stifel Nicolaus & Co. Inc. |
| 2025-12-01 | Lyon Joseph DouglasOfficer | 5K | $397K | 0.005% | 2025-12-01 | Stifel Nicolaus & Co. Inc. |
| 2025-12-01 | BELANOFF JOSEPH KOfficer | 40K | $3.2M | 0.038% | 2025-12-01 | Stifel Nicolaus & Company Inc. |
| 2025-11-25 | Guyer WilliamOfficer | 5K | $364K | 0.004% | 2025-11-25 | Fidelity Brokerage Services LLC |
| 2025-11-05 | Guyer WilliamOfficer | 20K | $1.4M | 0.019% | 2025-11-05 | Stifel Nicolaus & Company Inc. |
| 2025-11-03 | Lyon Joseph DouglasOfficer | 5K | $367K | 0.005% | 2025-11-03 | Stifel Nicolaus & Co. Inc. |
| 2025-11-03 | Maduck SeanOfficer | 20K | $1.5M | 0.019% | 2025-11-03 | Stifel Nicolaus & Co. Inc. |
| 2025-11-03 | BELANOFF JOSEPH KOfficer | 40K | $2.9M | 0.038% | 2025-11-03 | Stifel Nicolaus & Company Inc. |
| 2025-10-10 | Swisher Daniel N JRDirector | 2K | $193K | 0.002% | 2025-10-10 | Fidelity Brokerage Services LLC |
| 2025-10-07 | Guyer WilliamOfficer | 20K | $1.8M | 0.019% | 2025-10-07 | Stifel Nicolaus & Company Inc. |
| 2025-10-01 | Maduck SeanOfficer | 20K | $1.7M | 0.019% | 2025-10-01 | Stifel Nicolaus & Co. Inc. |
| 2025-10-01 | Lyon Joseph DouglasOfficer | 5K | $416K | 0.005% | 2025-10-01 | Stifel Nicolaus & Co. Inc. |
| 2025-10-01 | BELANOFF JOSEPH KOfficer | 40K | $3.3M | 0.038% | 2025-10-01 | Stifel Nicolaus & Company Inc. |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON2 holders report 5% or more of CORT in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 8.9% of the class (9,614,217 shares), filed 2026-10-27 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 5 | BlackRock, Inc.parent holding company | 9.6M | 8.9% | 2026-09-30 |
| 2026-08-13 | 13G/Ano. 6 | Renaissance Technologies LLCinvestment adviser | 5.3M | 4.9% | 2026-04-01 |
| 2026-08-13 | 13G/Ano. 6 | Renaissance Technologies Holdings Corporationparent holding company | 5.3M | 4.9% | 2026-04-01 |
| 2026-04-21 | 13G/Ano. 17 | INGALLS & SNYDER LLCbroker-dealer, investment adviser | 7.3M | 6.8% | 2025-12-31 |
| 2026-03-26 | 13G/Ano. 9 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding CORT at their latest 13F. JSON7 of the 30 tracked managers held CORT at their latest 13F, $839.6M in total at quarter-end prices. Renaissance Technologies is the largest at $457.5M (0.6% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 5.3M | $457.5M | 0.63% | -421K |
| AQR Capital Management | 2026-06-30 | 2.6M | $224.6M | 0.08% | +2.2M |
| D. E. Shaw & Co. | 2026-06-30 | 883K | $76.8M | 0.04% | -298K |
| Two Sigma Investments | 2026-06-30 | 610K | $53.0M | 0.04% | -336K |
| Millennium Management | 2026-06-30 | 153K | $13.3M | 0.00% | -406K |
| Citadel Advisors | 2026-06-30 | 109K | $9.5M | 0.00% | -145K |
| Bridgewater Associates | 2026-06-30 | 58K | $5.0M | 0.02% | +19K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Corcept Therapeutics reported revenue of $256.1M, up 31.7% from the same quarter a year earlier, and net income of $43.0M (0.36 diluted EPS). In FY 2025 it generated $142.0M of operating cash flow and spent $172.9M on buybacks.
- Cash
- $111.0M
- Equity
- $705.8M
- Total assets
- $888.7M
- Shares outstanding
- 108,098,397
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $256.1M | $43.0M | 16.8% | 0.36 |
| Q1 FY 2026 | 2026-03-31 | $164.9M | -$31.8M | -19.3% | -0.30 |
| Q4 FY 2025derived | 2025-12-31 | $202.1M | $24.3M | 12.0% | n/a |
| Q3 FY 2025 | 2025-09-30 | $207.6M | $19.7M | 9.5% | 0.16 |
| Q2 FY 2025 | 2025-06-30 | $194.4M | $35.1M | 18.1% | 0.29 |
| Q1 FY 2025 | 2025-03-31 | $157.2M | $20.5M | 13.1% | 0.17 |
| Q4 FY 2024derived | 2024-12-31 | $181.9M | $30.7M | 16.9% | n/a |
| Q3 FY 2024 | 2024-09-30 | $182.5M | $47.2M | 25.9% | 0.41 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $761.4M | $99.7M | $142.0M | $211K | $172.9M | n/a |
| FY 2024 | 2024-12-31 | $675.0M | $141.2M | $198.3M | $2.2M | $15.7M | n/a |
| FY 2023 | 2023-12-31 | $482.4M | $106.1M | $126.7M | $139K | $0 | n/a |
| FY 2022 | 2022-12-31 | $401.9M | $101.4M | $120.3M | $413K | $0 | n/a |
| FY 2021 | 2021-12-31 | $366.0M | $112.5M | $167.9M | $469K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-22 from the cover page.
What this page is
Corcept Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Corcept Therapeutics (CORT), SEC CIK 1088856, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-17.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-01.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-29.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1088856Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- SOLSSolstice Advanced Materials
- SOUNSoundHound AI
- SPCXSpaceX
- SPGSimon Property Group
- SPGIS&P Global
- SPHRSphere Entertainment
- SPOTSpotify Technology
- SRESempra
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
Datasets
Frequently Asked Questions
How much of CORT is sold short?
8,588,418 shares were held short at the 2026-10-15 settlement, 12.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CORT's daily short volume?
On 2026-10-28, 214,546 of the 431,459 CORT shares reported to FINRA were sold short, 49.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CORT have fails to deliver?
The SEC's latest file shows 70 CORT shares failed to deliver at settlement 2026-09-17. Fails are reported per settlement date and published twice a month with a lag.
Are CORT insiders buying or selling?
Insiders at CORT reported 46 open-market sells worth $44.8M in the last 90 days and no open-market buys. Latest filing: WILSON JAMES N (Director) on 2026-10-15.
Have CORT insiders filed to sell?
40 Form 144 notices on file for CORT worth $117.2M at the prices reported; 10 in the last 90 days worth $55.0M. Latest: Lyon Joseph Douglas filed on 2026-10-01 to sell 10,000 shares ($1.2M) from 2026-10-01.
Who owns 5% or more of CORT?
2 holders report 5% or more of CORT in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 8.9% of the class (9,614,217 shares), filed 2026-10-27 for an event on 2026-09-30.
What did CORT report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Corcept Therapeutics reported revenue of $256.1M, up 31.7% from the same quarter a year earlier, and net income of $43.0M (0.36 diluted EPS). In FY 2025 it generated $142.0M of operating cash flow and spent $172.9M on buybacks.
Which tracked 13F managers own CORT?
7 of the 30 tracked 13F managers held CORT shares at their latest filing, $839.6M in all. The largest: Renaissance Technologies (5.3M shares, $457.5M), Cliff Asness's AQR Capital Management (2.6M shares, $224.6M), D. E. Shaw & Co. (883K shares, $76.8M), Two Sigma Investments (610K shares, $53.0M), Izzy Englander's Millennium Management (153K shares, $13.3M), Ken Griffin's Citadel Advisors (109K shares, $9.5M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.